Related to VC Firm Partners with Amgen, Novartis to Form 15+ Biotech Startups

• Biotech Companies Face the Key Question—Deal or No Deal?
  Advice: Set aside dreams of becoming the next Amgen or Genentech; instead know when to partner, take the money, and run.
  
• Denosumab—Great Expectations for Amgen and Osteoporosis Market
  Serious side effects like skin infections requiring hospitalization could limit market penetration.
  
• Improving Working Capital—The Next Step in Big Pharma’s Transformation Efforts
  Better management of working capital could help firms get a better return rather than just driving top-line growth.
  
• Mergers and Acquisitions—The New IPO
  Tips for a strong communication strategy that will lure shareholders and investors over to your side.
  
• Virtual Development Models Become Biopharma’s Efficiency Initiative
  Such a strategy allows drug development to be driven by scientific data rather than a company’s survival or long-term stability.
  
• When Is Revenue Not Revenue for Biotech Firms?
  Proposed changes in accounting rules highlight complexity for public companies.
  
• BIO Investor: IPOs, Financing, and the Need for New Flu Treatments
  Presenters believe that M&A will shift to deals between biotech firms and that new technologies will improve vaccine production.
  
• How Biotech Unions Could Save Companies and Revitalize Pipelines
  Impetus for such mergers comes from the drying up of venture funds and pharma consolidation.
  
• New Uncertainty Regarding Disclosure of Adverse Effects
  Recent Matrixx Initiatives decision muddies requirements set forth in Carter-Wallace over a decade ago.
  
• Early-Stage Investors Hedge Their Bets with Medical Devices
  VCs are looking for a quicker return on their investments with less risk involved.
  
• Reporting from J.P. Morgan Healthcare Conference
  Drug companies developing companion diagnostics is just one of the trends highlighted at the meeting.
  
• Biotech Financing Overview and Trends from Last Year’s Fourth Quarter
  Biotechs are lining up to go public after a long wait.
  
• Amgen’s Biomarker Research Underlies Vectibix’ Success
  Next-generation sequencing technology is being used on Phase III trial data.
  
• Reporting from J.P. Morgan on Drug Development Companies
  Even the unseasonal cold couldn’t dampen the spirit of the biotech community.
  
• Marketing Innovations for Biotechs to Increase Revenues
  Looking outside the industry can bring breakthroughs.
  
• A Look at the Top Two Bio Clusters in the U.S.: California and Massachusetts
  Financing and workforce issues are at the top of their agendas for this year.
  
• Overview of the Number Three and Four Biotech Clusters in the U.S.
  North Carolina and Maryland are trying to start new funds to support start-ups.
  
• Review of the Second Tier of Biotechnology Clusters in the U.S.
  Colorado, Florida, New Jersey, Pennsylvania, and Washington gear up to boost growth plans while trying to balance budget woes.
  
• Supreme Court’s Decision in Matrixx v. Siracusano Calls for More Disclosure of Adverse Events to Investors
  Side effects that are not statistically significant must also be divulged.
  
• NY Biotech Leaders Pursue Empire State of Mind with One-Stop Shop Proposal
  Think tank is also promoting tax credit extensions, tailored incentives, and easier tech transfer as cures for state’s life science blues.